Novo Holdings led a $19m financing of AnaCardio.

Novo Holdings, Novo Nordisk Foundation's wholly owned holding company, led a $19m financing of AnaCardio, a clinical-stage biopharmaceutical company, with participation from Pureos Bioventures and Sound Bioventures, Flerie and Industrifonden. “Heart failure remains a devastating global health issue, affecting over 6 million individuals in the US and nearly 100 million worldwide. Current treatment options primarily address symptoms and risk factors but fail to target the underlying issue of reduced contractility. AC01 represents a breakthrough approach – a promising, safe inotrope with the potential to transform the treatment landscape. Novo Holdings is proud to support AnaCardio as it advances this critical innovation toward late-stage clinical development,” Jørgen Søberg Petersen, Novo Holdings Senior Partner.